Leading Paediatric Infectious Diseases-Current Trends, Gaps, and Future Prospects in Oral Pharmacotherapeutic Interventions

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2024 Jun 27

PMID 38931836

Authors

Penelope N Rampedi

Modupe O Ogunrombi

Oluwatoyin A Adeleke

Affiliations

Soon will be listed here.

Abstract

Paediatric infectious diseases contribute significantly to global health challenges. Conventional therapeutic interventions are not always suitable for children, as they are regularly accompanied with long-standing disadvantages that negatively impact efficacy, thus necessitating the need for effective and child-friendly pharmacotherapeutic interventions. Recent advancements in drug delivery technologies, particularly oral formulations, have shown tremendous progress in enhancing the effectiveness of paediatric medicines. Generally, these delivery methods target, and address challenges associated with palatability, dosing accuracy, stability, bioavailability, patient compliance, and caregiver convenience, which are important factors that can influence successful treatment outcomes in children. Some of the emerging trends include moving away from creating liquid delivery systems to developing oral solid formulations, with the most explored being orodispersible tablets, multiparticulate dosage forms using film-coating technologies, and chewable drug products. Other ongoing innovations include gastro-retentive, 3D-printed, nipple-shield, milk-based, and nanoparticulate (e.g., lipid-, polymeric-based templates) drug delivery systems, possessing the potential to improve therapeutic effectiveness, age appropriateness, pharmacokinetics, and safety profiles as they relate to the paediatric population. This manuscript therefore highlights the evolving landscape of oral pharmacotherapeutic interventions for leading paediatric infectious diseases, crediting the role of innovative drug delivery technologies. By focusing on the current trends, pointing out gaps, and identifying future possibilities, this review aims to contribute towards ongoing efforts directed at improving paediatric health outcomes associated with the management of these infectious ailments through accessible and efficacious drug treatments.

References

Hersh A, Shapiro D, Pavia A, Shah S . Antibiotic prescribing in ambulatory pediatrics in the United States. Pediatrics. 2011; 128(6):1053-61. DOI: 10.1542/peds.2011-1337. View

Beer K, Collier S, Du F, Gargano J . Giardiasis Diagnosis and Treatment Practices Among Commercially Insured Persons in the United States. Clin Infect Dis. 2017; 64(9):1244-1250. PMC: 5532738. DOI: 10.1093/cid/cix138. View

Bielicki J, Stohr W, Barratt S, Dunn D, Naufal N, Roland D . Effect of Amoxicillin Dose and Treatment Duration on the Need for Antibiotic Re-treatment in Children With Community-Acquired Pneumonia: The CAP-IT Randomized Clinical Trial. JAMA. 2021; 326(17):1713-1724. PMC: 8564579. DOI: 10.1001/jama.2021.17843. View

Chintu C, Bhat G, Walker A, Mulenga V, Sinyinza F, Lishimpi K . Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomised placebo-controlled trial. Lancet. 2004; 364(9448):1865-71. DOI: 10.1016/S0140-6736(04)17442-4. View

Walsh J, Bickmann D, Breitkreutz J, Chariot-Goulet M . Delivery devices for the administration of paediatric formulations: overview of current practice, challenges and recent developments. Int J Pharm. 2011; 415(1-2):221-31. DOI: 10.1016/j.ijpharm.2011.05.048. View

Assefa M . Multi-drug resistant gram-negative bacterial pneumonia: etiology, risk factors, and drug resistance patterns. Pneumonia (Nathan). 2022; 14(1):4. PMC: 9069761. DOI: 10.1186/s41479-022-00096-z. View

Venables R, Batchelor H, Hodson J, Stirling H, Marriott J . Determination of formulation factors that affect oral medicines acceptability in a domiciliary paediatric population. Int J Pharm. 2015; 480(1-2):55-62. DOI: 10.1016/j.ijpharm.2015.01.023. View

Chan G, Tang S . Parental knowledge, attitudes and antibiotic use for acute upper respiratory tract infection in children attending a primary healthcare clinic in Malaysia. Singapore Med J. 2006; 47(4):266-70. View

Shirley D, Tornel W, Warren C, Moonah S . Clostridioides difficile Infection in Children: Recent Updates on Epidemiology, Diagnosis, Therapy. Pediatrics. 2023; 152(3). PMC: 10471512. DOI: 10.1542/peds.2023-062307. View

10.

Turkova A, Wills G, Wobudeya E, Chabala C, Palmer M, Kinikar A . Shorter Treatment for Nonsevere Tuberculosis in African and Indian Children. N Engl J Med. 2022; 386(10):911-922. PMC: 7612496. DOI: 10.1056/NEJMoa2104535. View

11.

Jones M, Hama R, Del Mar C . Antivirals for treatment of influenza. Ann Intern Med. 2012; 157(5):385. DOI: 10.7326/0003-4819-157-5-201209040-00016. View

12.

Zheng W, Sun W, Simeonov A . Drug repurposing screens and synergistic drug-combinations for infectious diseases. Br J Pharmacol. 2017; 175(2):181-191. PMC: 5758396. DOI: 10.1111/bph.13895. View

13.

Rehman A, Simms V, McHugh G, Mujuru H, Ngwira L, Semphere R . Adherence to additional medication for management of HIV-associated comorbidities among older children and adolescents taking antiretroviral therapy. PLoS One. 2022; 17(6):e0269229. PMC: 9200347. DOI: 10.1371/journal.pone.0269229. View

14.

Sosnik A, Seremeta K, Imperiale J, Chiappetta D . Novel formulation and drug delivery strategies for the treatment of pediatric poverty-related diseases. Expert Opin Drug Deliv. 2012; 9(3):303-23. DOI: 10.1517/17425247.2012.655268. View

15.

Muringayil Joseph T, Mahapatra D, Esmaeili A, Piszczyk L, Hasanin M, Kattali M . Nanoparticles: Taking a Unique Position in Medicine. Nanomaterials (Basel). 2023; 13(3). PMC: 9920911. DOI: 10.3390/nano13030574. View

16.

Radtke K, Dooley K, Dodd P, Garcia-Prats A, McKenna L, Hesseling A . Alternative dosing guidelines to improve outcomes in childhood tuberculosis: a mathematical modelling study. Lancet Child Adolesc Health. 2019; 3(9):636-645. PMC: 7605863. DOI: 10.1016/S2352-4642(19)30196-8. View

17.

Bossu G, Autore G, Bernardi L, Buonsenso D, Migliori G, Esposito S . Treatment options for children with multi-drug resistant tuberculosis. Expert Rev Clin Pharmacol. 2022; 16(1):5-15. DOI: 10.1080/17512433.2023.2148653. View

18.

Harris A, Hicks L, Qaseem A . Appropriate Antibiotic Use for Acute Respiratory Tract Infection in Adults: Advice for High-Value Care From the American College of Physicians and the Centers for Disease Control and Prevention. Ann Intern Med. 2016; 164(6):425-34. DOI: 10.7326/M15-1840. View

19.

Dieterle M, Rao K, Young V . Novel therapies and preventative strategies for primary and recurrent Clostridium difficile infections. Ann N Y Acad Sci. 2018; 1435(1):110-138. PMC: 6312459. DOI: 10.1111/nyas.13958. View

20.

Wiedey R, Kokott M, Breitkreutz J . Orodispersible tablets for pediatric drug delivery: current challenges and recent advances. Expert Opin Drug Deliv. 2021; 18(12):1873-1890. DOI: 10.1080/17425247.2021.2011856. View